Sharekhan is bullish on Zydus Lifesciences has recommended buy rating on the stock with a target price of Rs 1078 in its ...

Legal battle over Zydus' biosimilar breast cancer drug could impact generic competition, Supreme Court refuses interim relief ...

The Supreme Court has instructed Zydus Lifesciences to approach the Delhi High Court. Zydus is seeking relief from an order ...

Zydus had approached the Supreme Court challenging the Delhi High Court's order, which prevented the company from producing ...

In July, a single-judge bench of the Delhi High Court restrained Zydus Lifesciences from selling its breast cancer drug in ...

Zydus Lifesciences Ltd shares closed at ₹ 948.95 on NSE on Tuesday following the Q2 results, 2.4% lower than the previous day ...

Upholding the patent rights of Swiss pharmaceutical giant F-Hoffmann-La Roche AG, the Delhi High Court has once again ...

The organic capex for the September quarter stood at nearly ₹302 crore, while it was ₹603 crore for the half year.

Zydus Lifesciences Q2 Results Live : Zydus Lifesciences declared their Q2 results on 12 Nov, 2024, reporting a notable ...

Zydus Lifesciences reported a 14% YoY net profit rise to Rs 911 crore for Q2FY25, driven by strong sales in India and the US.

October saw subdued growth in the Indian pharmaceutical market (IPM), with growth remaining in the low single digits, mainly ...